Literature DB >> 1540759

Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators.

.   

Abstract

The Cross-National Collaborative Panic Study, Phase Two, compared alprazolam with imipramine and with placebo in a sample of 1168 randomly assigned subjects. The study, conducted at 12 centres, assessed clinical change over eight weeks of double-blind drug treatment. Improvement occurred with alprazolam by week 1 and 2, and with imipramine by week 4. By the end of week 8, however, the effects of the two active drugs were similar to each other, and both were superior to placebo for most outcome measures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540759     DOI: 10.1192/bjp.160.2.191

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  25 in total

1.  Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.

Authors:  M R Mavissakalian; J K Schmier; J A Flynn; D A Revicki
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

2.  Time to response in panic disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone.

Authors:  David J Katzelnick; Johnaqa Saidi; Mark R Vanelli; James W Jefferson; James M Harper; Kay E McCrary
Journal:  Psychiatry (Edgmont)       Date:  2006-12

3.  Self- and observer assessment in anxiolytic drug trials: a comparison of their validity.

Authors:  W Maier; M Albus; R Buller; D Nutzinger; D Shera; P Bech
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

4.  Management of treatment-resistant panic disorder.

Authors:  Richard L Holt; R Bruce Lydiard
Journal:  Psychiatry (Edgmont)       Date:  2007-10

Review 5.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

6.  Panic disorder and its subtypes: a comprehensive analysis of panic symptom heterogeneity using epidemiological and treatment seeking samples.

Authors:  R Roberson-Nay; K S Kendler
Journal:  Psychol Med       Date:  2011-04-18       Impact factor: 7.723

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  [Significance of GABAA receptors for the pathophysiology and therapy of panic disorders].

Authors:  R Rupprecht; P Zwanzger
Journal:  Nervenarzt       Date:  2003-06-24       Impact factor: 1.214

9.  Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?

Authors:  W Maier; S M Roth; N Argyle; R Buller; P Lavori; S Brandon; O Benkert
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.